Mutant Human Embryonic Stem Cells Reveal Neurite and Synapse Formation Defects in Type 1 Myotonic Dystrophy  by Marteyn, Antoine et al.
Cell Stem Cell
Short ArticleMutant Human Embryonic Stem Cells
Reveal Neurite and Synapse Formation
Defects in Type 1 Myotonic Dystrophy
Antoine Marteyn,1,3 Yves Maury,2 Morgane M. Gauthier,1 Camille Lecuyer,2 Remi Vernet,1 Je´roˆme A. Denis,1
Genevie`ve Pietu,1 Marc Peschanski,1 and Ce´cile Martinat1,*
1INSERM/UEVE UMR 861
2CECS
I-STEM AFM, 5 rue H. Desbrue`res 91030 Evry Cedex, France
3Present address: Ectycell S.A., 93230 Romainville, France
*Correspondence: cmartinat@istem.fr
DOI 10.1016/j.stem.2011.02.004SUMMARY
Myotonic dystrophy type 1 (DM1) is a multisystem
disorder affecting a variety of organs, including the
central nervous system. By using neuronal progeny
derived from human embryonic stem cells carrying
the causal DM1 mutation, we have identified an early
developmental defect in genes involved in neurite
formation and the establishment of neuromuscular
connections. Differential gene expression profiling
andquantitativeRT-PCRrevealeddecreasedexpres-
sion of two members of the SLITRK family in DM1
neural cells and in DM1 brain biopsies. In addition,
DM1 motoneuron/muscle cell cocultures showed
alterations that are consistent with the known role of
SLITRK genes in neurite outgrowth, neuritogenesis,
and synaptogenesis. Rescue and knockdown exper-
iments suggested that the functional defects can be
directly attributed to SLITRK misexpression. These
neuropathological mechanisms may be clinically
significant for the functional changes in neuromus-
cular connections associated with DM1.
INTRODUCTION
Myotonic dystrophy type 1 (DM1) is the most common inherited
muscular dystrophy in adults, mainly characterized by muscle
wasting and delayed relaxation after muscle contraction
(myotonia). The disease is nevertheless pleiotropic and affects
a number of other organs and functions (Harper, 2001), specifi-
cally the central nervous system (CNS). Cognitive impairment
and excessive sleepiness have been clinically identified in DM1
patients (de Leo´n and Cisneros, 2008), while motor neuron axon-
opathy has been observed in postmortem examination (Cros
et al., 1988; Krishnan and Kiernan, 2006). Mental retardation in
individuals with congenital DM1 has also been associated with
defects in developmental processes (Dyken and Harper, 1973).
The molecular mechanisms underlying the neuropathology in
DM1 are mostly unknown. The disease is due to an inherited
unstable expansion of CTG triplet repeats located within the434 Cell Stem Cell 8, 434–444, April 8, 2011 ª2011 Elsevier Inc.30-untranslated region of the dystrophia myotonica-protein
kinase gene (DMPK). Although defects related to DMPK protein
levels may contribute to some of the observed clinical features
(Llagostera et al., 2007; Saba et al., 1999), the current accepted
molecular model suggests that most symptoms are associated
with trans-dominant alterations of RNA processing (Cooper
et al., 2009; Wheeler, 2008). DMPK transcripts with expanded
CUG repeats accumulate in the cell nucleus instead of being
exported to the cytoplasm. They form intranuclear inclusions
(foci) by aggregating nuclear proteins, some of which are
involved in RNA splicing and stabilization such as MBNL1. This
sequestration of RNA-processing proteins in foci leads to
a decrease in their activity and, consequently, to impaired alter-
nate splicing and abnormal expression of a large number of
genes. This translates into a wide spectrum of affected organs
and clinical symptoms in DM1 (Cooper et al., 2009; Osborne
et al., 2009; Ranum and Cooper, 2006). In the CNS, defects in
alternate splicing have previously been demonstrated, for
instance, in the glutamate NMDA receptor 1 and Tau protein
(Jiang et al., 2004; Sergeant et al., 2001). Although these two
genes have important functional roles that can explain some of
the DM1 neuropathology, several other genes remain to be iden-
tified and linked to specific functional alterations in the CNS and
other organ systems (Osborne et al., 2009).
Our aim was to search for new molecular mechanisms of the
DM1 neuropathology by using pluripotent stem cell lines derived
from embryos characterized during preimplantation genetic
diagnosis as carrying the gene for this disease. These cells can
self-renew indefinitely, making them available in large numbers.
These were used to perform a whole-genome transcriptomic
analysis. Their ability to differentiate into any cell lineage allowed
us to perform functional studies to evaluate the development of
neuromuscular connections. Based on these complementary
approaches, this report describes a neuropathological mecha-
nism for DM1 that links gene defects in neural lineage with
a dysfunction in neurite outgrowth and synaptogenesis.
RESULTS
TwoDM1-affected human embryonic stem cell (hESC) lines from
independent couples were derived after preimplantation genetic
diagnosis, VUB03_DM and VUB24_DM (Mateizel et al., 2006).
Table 1. Gene with Modulations in at Least One of the Three Cell Type Populations
Gene Downregulated in VUB03_DM
Gene Title Gene Symbol
Chromosome
Number Entrez Gene Unigene
Fold Change
hES
Fold Change
NPC
Fold Change
MPC
Zinc finger protein 37a
(KOX 21)
ZNF37A chr10 7587 Hs.292575 3.78 11.85 10.71
Proteasome (prosome,
macropain) 26S subunit,
non-ATPase, 5
PSMD5 chr9 5711 Hs.193725 8.34 3.21
Zinc finger protein 248 ZNF248 chr10 57209 Hs.25275 54.62
SLIT and NTRK-like
family, member 4
SLITRK4 chrX 139065 Hs.272284 20.84
EPH receptor A5 EPHA5 chr4 2044 Hs.479853 22.36
Paired related homeobox 1 PRRX1 chr1 5396 Hs.283416 9.22
Nicotinate
phosphoribosyltransferase
domain containing 1
NAPRT1 chr8 93100 Hs.493164 7.72
Ribosomal protein L31 RPL31 chr2 6160 Hs.518551 6.17
Gene Upregulated in VUB03_DM
Gene Title Gene Symbol
Chromosome
Number Entrez Gene Unigene Fold Change Fold Change Fold Change
Trafficking protein particle
complex 3
TRAPPC3 chr1 27095 Hs.523131 2.61 3.20
Cathepsin B CTSB chr8 1508 Hs.520898 2.09 3.17
Maternally expressed 3 MEG3 chr14 55384 Hs.279815 8.79 90.57
NAD(P)H dehydrogenase,
quinone 2
NQO2 chr6 4835 Hs.533050 5.16 3.08
Interleukin 13 receptor,
alpha 1
IL13RA1 chrX 3597 Hs.496646 5.41
Eukaryotic translation
initiation factor 2, subunit 3
gamma, 52 kDa
EIF2S3 chr12 1968 Hs.539684 2.57
Prickle-like 1 (Drosophila) PRICKLE1 chr12 144165 Hs.524348 2.92
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Defective Neurite Outgrowth in DM1These lines carry a mutant DMPK gene that contains within the
30UTR region approximately 1000 and 3000 CTG triplet repeats,
respectively (Figure S1 available online). The size of the CTG
triplet repeats remains quite stable during culture (Figure S1).
Three wild-type hESC lines were used as controls (VUB01,
SA001, and H9). There was no alteration of cell growth or differ-
entiation capacity for DM1 cells compared to controls. DMPK
mRNA was expressed at similar levels in DM1-affected and
control cells (Figure S1).Effects of Mutant RNA on Gene Expression in DM1
Human ESCs and Their Progenies
To identify differentially expressed genes associated with DM1 in
neural cells, VUB03_DM cells were compared with two wild-type
hESC lines (VUB01 and SA001) and the results confirmed with
quantitative RT-PCR in VUB24_DM and H9. Cells were either
kept undifferentiated (hESC) or were differentiated into neural
precursor cells (NPC) (Perrier et al., 2004). Human ESC-derived
mesenchymal precursor cells (MPC) were used as an additional
control for neural specificity of gene expression (Denis et al.,
2011; Mateizel et al., 2008). Differentiation processes do not
modify the size of CTG triplet repeats (Figure S1).A whole-gene expression profiling was performed with Affy-
metrix whole-genome DNA chips (Figure S1). Principal compo-
nent analysis showed similar expression profiles between the
DM1 and the wild-type cell lines at the same differentiation
stage, indicating that the effects of DM1 mutation on gene
expression were probably subtle (Figure S1). Observed changes
in expression were further confirmed with quantitative real-time
RT-PCR for 15 genes in VUB03_DM and VUB24_DM relative to
at least one of the three cell types studied (Table 1). These
15 genes, 8 downregulated and 7 upregulated, are involved in
a large spectrum of cellular functions ranging from transcription
regulation to cell migration.
We focused on SLITRK4 because it is specifically downregu-
lated in DM1 neural precursor cells. The SLITRK family of
proteins has been shown to play a role in neurite outgrowth
(Aruga and Mikoshiba, 2003; Aruga et al., 2003). We performed
a comparative analysis of neurite outgrowth in DM1 and control
neural progenies to identify any potential functional defects.
Functional Analysis of Neuritogenesis
and Synaptogenesis in DM1 Neurons
We chose to differentiate DM1 hESCs into motoneurons,
because this a potential model of synaptogenesis in cocultureCell Stem Cell 8, 434–444, April 8, 2011 ª2011 Elsevier Inc. 435
Figure 1. DM1-hESC-Derived Cholinergic Cells Have Cellular and Molecular Features of DM1
(A) Immunostaining directed against specific markers of cholinergic differentiation: Islet-1, Hb9, and VAChT. Nuclei are stained with Dapi and neuronal cells with
TuJI antibody. Scale bars represent 50 mm. For VAChT, scale bars represent 20 mm.
(B) Quantification of Islet-1-, Hb9-, and VAChT-positive cells for VUB03_DM, VUB01, and H9 cell lines at 42 and 55 days in vitro. See also Figures S1 and S2.
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Defective Neurite Outgrowth in DM1with muscle cells. A differentiation protocol, modified from ex-
isting ones (Martinat et al., 2006; Wichterle et al., 2002), was
developed with the inductive factors Sonic Hedgehog (Shh)
and retinoic acid (RA) (Figure S2). Differentiation was analyzed
by immunocytochemistry (Figures 1A and 1B; Figure S2) and
quantitative RT-PCR (Figures 1C and 1D; Figure S2). During
neural induction, expression of pluripotency markers were
rapidly lost whereas the neural marker PAX6 was detected
(Figure S2). ISLET-1, an early marker of postmitotic motoneu-
rons, also peaked at that stage (Figures 1C and 1D). At
later stages, approximately 30% of TuJI-positive neurons
expressed the motoneuron marker Hb9. Approximately 15%
of cells showed a more mature cholinergic phenotype, as re-
vealed by the expression of the vesicular acetylcholine trans-
porter, VAChT (Figures 1A and 1B). No change in motoneuron
markers was observed in DM1 cells when compared to
controls, whether quantitatively or in their temporal appearance
(Figures 1C and 1D; Figure S2). No defect was found in other
cell types such as GABAergic neurons and astrocytes
(Figure S2).
Nuclear aggregation of mutant DMPK RNA was mainly de-
tected in neuronal cells showing a motoneuron phenotype
(Figures 1E and 1F). As described in patients’ cells, these nuclear
aggregates colocalized with the splicing factor MBNL1 (Fig-
ure S2). As a result, altered splicing of NMDAR1 was also
observed, which reproduces the defect described in DM1
patients (Jiang et al., 2004) where the expression of the isoform
containing exon 5 is increased (Figure 1G).
Comparative analysis of neurite outgrowth was performed
with panneuronal MAP2 and TuJI antibodies. Data showed
a significant increase in overall MAP2 immunoreactivity in DM1
cells when compared to controls, without any significant differ-
ences in the number of neuronal cell bodies (Figures 2A and
2B). Similar results were observed with TuJI (Figure S2). Neurite
outgrowth for GABAergic and dopamine neurons are not
different between DM1 and control cells, suggesting that neurite
growth in nonmotor neurons is not affected.
Coculture of hESC-derived neurons with human primary myo-
tubes (Mu2bR3 cells) was then performed to determine the
potential impact of neurite outgrowth alteration on synaptogen-
esis. Neuromuscular junctions were quantified via the codetec-
tion of the neuronal presynaptic marker TuJ1 and alpha
bungarotoxin (BTX), which labels postsynaptic aggregation of
acetylcholine receptors (Figure 2C). The significantly larger neu-
rite network in DM1 cultures was associated with a significant 5-
to 10-fold decrease in the number of neuromuscular contacts
when compared to controls (Figure 2D). In summary, DM1 cells
were characterized by abundant neuritogenesis associated
with a significant impairment in the formation of neuromuscular
connections.(C) Quantitative real-time RT-PCR for the expression of regulatory genes Olig2, I
lines and VUB01 and H9 wild-type cell lines. Data (n = 3) are presented as value
(D) Expression of Olig2, Isl1, VAChT, and ChAT on VUB03_DM cholinergic culture
(E) Nuclear colocalization of mutant mRNA (red) and markers for neuronal cells (T
immunostaining. Scale bars represent 20 mm. Nuclei were stained with Dapi.
(F) Quantification of positive cells with foci in VUB03_DM cells at 40 days of diffe
(G) Expression of the NMDAR1 containing exon 5 isoform in VUB03_DM and VUB
standard error of the mean (SEM) and were analyzed by ANOVA followed by StuRelationship between the SLITRK Genetic Defect
and Abnormal Neuritogenesis in DM1
The gene expression and functional comparative analyses
provided circumstantial evidence of a relationship between
SLITRK4 downregulation and alteration in neurite outgrowth and
synaptogenesis in DM1 cell cultures. By using quantitative PCR,
we systematically screened DM1 cells for the expression of other
genes thatmaybe involved in neurite outgrowth (ChenandCheng,
2009; Guan and Rao, 2003): the six members of the SLITRK gene
family, five ephrin ligands and receptors, Robo1, three semaphor-
ins, DCC, neurogenin, and neuropilin. This analysis confirmed the
downregulation of SLITRK4 expression and showed a change in
the expression only of the closely related SLITRK2 gene (Figures
3A–3G); no other tested gene was altered (Figure 3A). Because
SLITRK2 and SLITRK4 are located in the same region Xq27 of
the X chromosome, additional genes located in the same portion
were studied. No defect in any of these genes was observed
(Figures 3B–3E; Figure S3). Chromosomal integrity was also veri-
fied by CGH array analysis (data not shown).
The relationship between decreased expression of SLITRK2
and SLITRK4 in myotonic dystrophy type 1 was confirmed by
quantitative RT-PCR bymeans of brain tissue samples from fetal
and adult patients (Figure 3H). Again, no alteration was found of
any of the other screened neurite outgrowth genes (Figure S3).
The presence of CTG repeat expansion also directly affects
DMPK expression, so we investigated, in control hESC-derived
neurons, whether downregulation of DMPK expression played
a role in modulating SLITRK expression or neurite outgrowth.
As shown in Figure S4, DMPK does not appear to be involved
in SLITRKmisexpression or in neurite outgrowth. In addition, dis-
rupted splicing by MBNL1 does not seem to be involved in the
defective expression of the two SLITRK genes, as shown by
the fact that transfection of DM1 and control cells with siRNA
to specifically knock down MBNL1 did not significantly change
their expression (data not shown).
Additional experiments were performed with DM1 cells to
demonstrate the relationship between defects in SLITRK2 and
SLITRK4 expression and functional alteration in neuritogenesis.
First, rescue of the functional defect was carried out by transitory
plasmid nucleofection (Amaxa technology) with SLITRK2 and
SLITRK4 constructs into DM1 cell cultures. The majority of the
cells were transiently transfected, based on the expression of
a GFP construct (70% ± 9% SEM). One week after transfection,
overexpression of the two genes had restored neurite length
back to control levels (Figures 4A–4C; Figure S4). Overexpres-
sion of each SLITRK gene separately was as effective as their
combination (Figure 4C), suggesting that these genes are redun-
dant. Consistent with previous results obtained in mouse
neuronal cells (Aruga and Mikoshiba, 2003), we found that over-
expression of SLITRK3 and SLITRK6 also decreased neuritesl1, VAChT, and ChAT during cholinergic differentiation of the VUB03_DM cell
s of the undifferentiated state after normalization with cyclophilin A levels.
by quantitative RT-PCR analysis is similar to VUB01 and H9 control cell lines.
uJI and Isl1) or glial cells (GFAP) (green) by in situ hybridization combined with
rentiation in the different neural populations (n = 3). See also Figure S2.
24_DM in comparison to H9 control cell line. Data (n = 3) are shown as mean ±
dent’s t test, p < 0.05.
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Figure 2. DM1 Mutation Results in an Excessive Neurite Network and a Small Number of Neuromuscular Junctions
(A) Immunostaining for the panneuronal marker TuJI (green) at 62 days in vitro in two DM1 cell lines (VUB03_DM and VUB24_DM) and two wild-type cell lines
(VUB01 and H9). Nuclei are stained with Dapi. Scale bars represent 50 mm. See also Figure S2.
(B) MAP2-positive neural cells (both in percentage and present per cm2), neurite length, and MAP2 area per neuron were quantified with the image analysis
instrument ArrayScan VTI HCS Reader (n = 4). Data are shown as mean ± SEM and were analyzed by ANOVA followed by Student’s t test. *p% 0.05.
(C) Detection of neuromuscular junction by double immunostaining for TuJI (red) and alpha bungarotoxin (a-BTX) (green) in VUB03_DM andWT_H9 cell lines after
8 and 16 DIV in coculture of neural progenitor cell and human myotubes.
(D) Quantification of neuromuscular junction after 8 and 16 days of cocultures in H9_WT, VUB03_DM, and VUB24_DM. Data (n = 3) are shown asmean ±SEM and
were analyzed by ANOVA followed by Student’s t test. *p% 0.005.
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Defective Neurite Outgrowth in DM1outgrowth (Figure S4), which demonstrates the redundancy of
these proteins. Conversely, stable knockdown of SLITRK2 and
SLITRK4 in neurons derived from wild-type cultures, by means
of shRNA-recombinant lentiviral vectors, induced a 2- to 3-fold
increase in neurite length, compared to control cells treated438 Cell Stem Cell 8, 434–444, April 8, 2011 ª2011 Elsevier Inc.with a GFP shRNA (Figures 4D–4F; Figure S4). Under these
conditions, approximately 79% ± 11% SEM of cells were trans-
duced. However, in these latter experiments the knockdownwas
not specific because each construct affected several SLITRK
genes (Figure S4).
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Figure 3. Specific Downregulation of the Expression of Two SLITRK Family Members in Association with the DM1 Mutation
(A) Quantitative RT-PCR for neurite outgrowth genes at day 62 of cholinergic differentiation in VUB03_DM compared to the wild-type H9 cell line. Data (n = 3) are
shown as mean ± standard error of the mean (SEM) and were analyzed with Dunnett’s test.
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Defective Neurite Outgrowth in DM1DISCUSSION
The main result of the present study was the identification of
a functional neuropathological defect in DM1 that impairs both
neuritogenesis and synaptogenesis at an early developmental
stage. This functional defect is associated with an abnormally
low expression of two genes that belong to the SLITRK family.
Extensive data exist showing the involvement of the CNS in
DM1: psychological dysfunction, mental retardation, excessive
daytime sleepiness, and neuropathological abnormalities (Abe
et al., 1994; Damian et al., 2001; de Leo´n and Cisneros, 2008;
Delaporte, 1998; Meola et al., 2003; Modoni et al., 2004; Park
and Radtke, 1995; Sistiaga et al., 2010; Turnpenny et al.,
1994). Potential defects in neuritogenesis and synaptogenesis
have also been suggested. DMPK has been proposed to have
a role in the formation of the neuromuscular junction and signal
transmission (van der Ven et al., 1993). Although this hypothesis
has not been further substantiated, pathological motoneuron
defects have been found in DM1. Ribonuclear aggregates of
mutated DMPK RNA have been observed in the spinal motoneu-
rons of patients (Wheeler et al., 2007). In neuromuscular junc-
tions, synaptic hyperproliferation (Nagao et al., 2003), demyeli-
nated nerve fibers (Panaite et al., 2008), and abnormal
morphological motor nerve terminals (Pachter and Eberstein,
1986; Panaite et al., 2008; Stranock and Davis, 1978) have
been described in DM1 patients and animal models of the
disease. Our results are consistent with these observations
and indicate that functional defects in neuritogenesis and synap-
togenesis at the neuromuscular junction may be associated with
DM1 at an early developmental stage.
The intracellular domains of SLITRK are similar to those of the
TrkA neurotrophin receptor involved in NGF-induced neurite
outgrowth (Blo¨chl and Blo¨chl, 2007). Thus, similarities between
the carboxy-terminal domain and Trk neurotrophin receptor
suggests that SLITRKs could be involved in neurite outgrowth
via PLCg-mediated signaling and, as a consequence, actin
assembly and disassembly (Reichardt, 2006). It has been shown
that transient expression of mouse Slitrk2 and 4 in rodent PC12
pheochromocytoma cells results in a strong inhibition of neurite
outgrowth (Aruga and Mikoshiba, 2003). The extracellular
domains of SLITRK proteins share structural characteristics
with the Slit/Robo family, which has been extensively studied
(Ypsilanti et al., 2010). Similar to other protein families involved
in neurite outgrowth and synaptic site recognition such as eph-
rins, netrins, and semaphorins, Slit/Robo proteins are respon-
sible for the fine tuning of pre- and postsynaptic partners. A
similar role for SLITRK proteins can be hypothesized based on
the defects observed in DM1 cells. Indeed, the relationship
between the abundant neuritogenesis and loss of synaptogene-
sis may reflect a slight alteration in recognition signals between
the two synapse partners. Other members of the SLITRK family
have been recently implicated in neurological dysfunctions.(B) Schematic localization of SLITRK2 and SLITRK4 on the chromosome Xq27 re
(C–E) Quantitative RT-PCR for SLITRK2 and SLITRK4 in VUB03_DM in the undiffe
Data (n = 5) are shown as mean ± SEM and were analyzed with Dunnett’s test. S
(F and G) SLITRK2 and SLITRK4 expression by real-time RT-PCR in the second
entiation compared to the control H9 cell line at the same differentiation state. D
(H) Quantitative RT-PCR analysis of expression of SLITRK2 and SLITRK4 in fetal
440 Cell Stem Cell 8, 434–444, April 8, 2011 ª2011 Elsevier Inc.SLITRK1may be involved in obsessive-compulsive disorder, tri-
chotillomania (Zuchner et al., 2006), as well as in Tourette
syndrome (Katayama et al., 2009, 2010; O’Rourke et al., 2009).
SLITRK6 can play a role in the sensory neural development of
the inner ear and its dysregulation may lead to defects in coordi-
nation and balance (Katayama et al., 2009).
The molecular basis of the effect of DM1 on expression of
SLITRK2 and 4 remains elusive. Although we cannot completely
exclude a defect in alternate splicing or stabilization, knocking
down MBNL1, the most important splicing factor indirectly
affected by the DM1 mutation, did not have effect. Although
the currently accepted pathological model of DM1 suggests
that manifestations are the result of the alteration of proteins
involved in pre-mRNA splicing, recent studies have shown that
DM1 pathology cannot be completely attributed to these mech-
anisms. Evidence suggests that CUG expansion in RNA can
interfere with both transcriptional and posttranscriptional activi-
ties (Osborne et al., 2009; Yadava et al., 2008). Although the
exact mechanisms are still unclear, it could be attributed in
part to the leaching of transcription factors from chromatin and
their sequestration by the mutant DMPK RNA (Ebralidze et al.,
2004).
Our search for additional molecular actors involved in DM1 led
us to undertake a resource-driven approach. The objective was
to identify differentially expressed genes in cells carrying the
DM1 gene by comparison with controls. We based our approach
on hESCs derived from preimplantation genetic diagnosis (PGD)
for DM1 (Mateizel et al., 2006). As mentioned earlier, hESC lines
have two advantages: the ability to generate an unlimited source
of cells and differentiate into homogenous cell populations of
discrete phenotypes (Fenno et al., 2008). As a complement for
such studies, the genomic defect of in cell lines can be precisely
characterized by PGD (Mateizel et al., 2006). The use of PGD-
derived hESCs has been instrumental in the study of the molec-
ular mechanisms of Fragile X syndrome (Eiges et al., 2007). The
conversion of somatic cells, such as human skin fibroblasts, into
induced pluripotent cells (iPSCs) by genetic manipulation
provides new opportunities to generate stem cells to model
any disorder (Yoshida and Yamanaka, 2010). Our results
contribute to demonstrating the value of human pluripotent
stem cells as an appropriate model to decipher events involved
in the pathogenesis of a disease state.EXPERIMENTAL PROCEDURES
Human ESC Culture
The project of using hESC lines from affected embryos for DM1 was licensed
by the French BioMedicine Agency in August 2005 (RECR0500141A). Mutant
hESC lines (VUB03_DM, XX, passages 60–80; and VUB24_DM; XX, passages
30–40, derived in AZ-VUB) and wild-type human ESCs (H9, XX, passages
40–60; WiCell Research Institute; SA001, XY, passages 36–41, Cellartis;
VUB01, XY, passages 80–90) (Mateizel et al., 2006) were cultured as previously
described (Lefort et al., 2008).gion.
rentiated state (DIV 0), NPC (DIV 36), and mature motor neurons state (DIV 62).
ee also Figure S3.
mutant cell line VUB24_DM at undifferentiated state and 62 days after differ-
ata (n = 5) represent the means ± SEM and were analyzed by Dunnett’s test.
and adult brains of control and DM1 patients. Each plot represents a patient.
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Defective Neurite Outgrowth in DM1Cholinergic Differentiation and Coculture with Muscular Cells
Cholinergic differentiation and coculture with muscular cells were modified
from exiting protocols (Braun et al., 1996; Wichterle et al., 2002) and are
described in detail in the Supplemental Experimental Procedures.
Immunocytochemistry and In Situ Hybridization
Immunocytochemistry was performed as described (Martinat et al., 2006). The
primary antibodies used are listed in the Supplemental Experimental Proce-
dures. Secondary antibodies conjugated with FITC or Cy3 (1/1000) (Jackson
ImmunoResearch) were used. Nuclei were stained with 4,6-diamidino-2-phe-
nylindole (DAPI) (1/10,000). In situ hybridization was performed to detect the
accumulation of pathological RNA with an Alexa555 labeled (CAG)10 oligonu-
cleotide probe (Operon). Images were captured with a fluorescent Zeiss
microscope.
RNA Extraction and Real-Time RT-PCR
Total RNA from cells was extracted according to the ‘‘RNeasy Mini Protocol’’
(QIAGEN, Courtaboeuf, France). Reverse transcription was performed with
SuperScript III reverse transcriptase (Invitrogen, Cergy Pontoise, France).
Real-time PCR was performed with SyberGreen PCR Master Mix (Applied Bi-
osystems) on aChromo4Real-Time system (Bio-Rad). The primers are listed in
Table 2. All the amplified products were verified by sequencing.
Plasmids
SLITRK2, 4, 3, and 6 cDNA were cloned as described in the Supplemental
Experimental Procedures.
Transient Plasmid Nucleofection
Amaxa nucleofection was performed with the Rat Neural Stem Cell Nucleofec-
tor Kit (Lonza) according to the manufacturer’s protocol (Amaxa). In brief,
VUB03_DM and H9 neural rosettes were collected at day 16 and resuspended
at 4 3 106 cells in 100 ml of nucleofection solution containing 4 mg of plasmid
(GFP, SLITRK2-pcDNA3, SLITRK4-pcDNA3) for each condition. The cells
were then plated on polyornithine/laminin-coated dishes in N2 medium sup-
plemented with Shh (300 ng/ml), BDNF (20 ng/ml), RA (30 ng/ml), and laminin
(100 ng/ml). Medium was changed every day. RNA was extracted 3 days after
plating and cells were fixed about 10 days later.
DM1 Tissues
Fetal brain RNA (gift of Dr. G. Gourdon) was obtained from 12- to 25-week-old
fetuses. DM1 samples were affected to different degrees (97–1500 CTG
repeats). Postmortem brain RNA (gift of Dr. A. Delacourte) were obtained
from frontal cortex biopsies of six patients (three DM1 [DS61; GOS4; BAS3]
and three controls [BA72; D165B; HO60]).
shRNA SLITRK Lentiviral Transduction
Lentiviral shRNA SLITRK transduction was performed with ‘‘NM_173078/SLIT
and NTRK-like family, member 4/MISSION shRNA Lentiviral Transduction
Particles/clone TRCN0000078623/NM_173078.2-3203s1c1,’’ ‘‘NM_032539/
SLIT and NTRK-like family, member 2/MISSION shRNA Lentiviral Transduc-
tion Particles/clone TRCN0000153670/NM_032539.2-4826s1c1,’’ and
‘‘MISSION Control Transduction Particles’’ (Sigma-Aldrich).
In brief, VUB01 and VUB03_DM neural rosettes were collected and 83 105
cells were resuspended for each condition. The lentiviral infection was per-
formed at an MOI of 1 in 40 ml of lentiviral supernatant. Then, cells were platedFigure 4. Neurite Outgrowth Rescued by SLITRK2 and SLITRK4 Overe
(A) Immunostaining for TuJI 7 days after SLITRK2 and SLITRK4 transfections into
with Dapi. Scale bar represents 50 mm. See also Figure S4.
(B and C) Histograms represent the number of neurons present per cm2 at the tim
cells (C) in VUB03_DM transfected by a GFP control plasmid, pcDNA3-SLITRK
transduced by a GFP control shRNA.
(D) Immunostaining for TuJI 7 days after shRNA SLITRK2 and shRNA SLITRK4 tra
line was used as a positive control. Nuclei are stained with Dapi. Scale bar repre
(E) Histograms represent the number of neurons present per cm2 at the time of a
VUB01 transduced by aGFP control shRNA,SLITRK2 shRNA, SLITRK4 shRNA, an
the image analysis instrument ArrayScan VTI HCS Reader. Data (n = 3) are show
442 Cell Stem Cell 8, 434–444, April 8, 2011 ª2011 Elsevier Inc.on polyornithine/laminin-coated dishes with N2 medium supplemented with
Shh (300 ng/ml), BDNF (20 ng/ml), RA (30 ng/ml), and laminin. Medium was
changed every day. RNA was extracted 3 days after plating and cells were
fixed about 10 days later.
Array Scan Analysis
Outgrowth of the neurite network was analyzed with an ArrayScan VTI HCS
Reader (Cellomics). Data including the number of neural cells, expansion
area, length, intensity, and number of neurites were collected with cell select-
ing software (Cellomics). Pictures were acquired with a 203 objective in high-
resolution camera mode and were analyzed based on the ‘‘Neuronal profiling’’
bioapplication. The first channel was used for nucleus identification (DAPI
staining) and the second channel was used to identify cell bodies and then
neurites from valid cell bodies (based on intensity thresholds and segmenta-
tion parameters). Data including the number of neural cells, expansion area,
length, intensity, and number of neurites were collected with VHCS view soft-
ware (Cellomics). Parameters such as neurite area per neuron corresponded
to the area of all the identified neurites from valid cell bodies (count3 length3
width) divided by the number of valid cell bodies.
Statistical Analysis
Statistical comparisons included Student’s t test and analysis of variance
(ANOVA), followed by post hoc analysis with Dunnett’s test. The cut-off for
statistical significance was set at p < 0.05. Statistical analysis was performed
with JMP7 software. Data are shown as mean ± standard error of the mean
(SEM).
ACCESSION NUMBERS
The microarray data are available in the Gene Expression Omnibus (GEO)
database (http://www.ncbi.nlm.nih.gov/gds) under the accession number
GSE7214.
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Table 2. List of Primers Used for the Study
Gene Nucleotide Sequence
Actin F CTC TTC CAG CCT TCC TTC CT
R AGC ACT GTG TTG GCG TAC AG
Calbindin1 F TCA GGA CGG CAA TGG ATA CA
R AAG AGC AAG ATC CGT TCG GT
ChAT F GAC TCG CTG GAC ATG ATT GA
R TGC AGG GAC TTG TCG TAC C
CXorf1 F TCT GCT CAA GCA CTT TCG AC
R CAT TTT GCT GTG CTG ATG CT
Cyclophilin A F CCC ACC GTG TTC TTC GAC AT
R CCA GTG CTC AGA GCA CGA AA
DARPP32 F CCT GAA GGT CAT CAG GCA GT
R GGT CTT CCA CTT GGT CCT CA
DCC F AGA CGT CTG AGG TGC GAC TT
R ATG TGC AGT CAT GCT CCA AG
EphA1 F TGC AGC AGT ATA CGG AGC AC
R TTG ATG TCG TCG TTG GTC AT
EphA2 F TGC AGC AGT ATA CGG AGC AC
R TTG ATG TCG TCG TTG GTC AT
EphA4 F CAT GAA GCT GAA CAC CGA GA
R GAC GTA TCA GCC CCT GTG AT
EphA5 F GAC TGC CCC AGA AGC AAT AG
R TTG GTC ATC TCC CAG TAG GG
EphB1 F CTT ACG AGG ATC CCA ACG AA
R CAA ACG CCC CTT GTA CAC TT
GFAP F CAG GAC CTG CTC AAT GTC AA
R ATC TCC ACG GTC TTC ACC AC
HoxC8 F CTC AGG CTA CCA GCA GAA CC
R TTG GCG GAG GAT TTA CAG TC
Isl1 F AGC AGC CCA ATG ACA AAA CT
R TTT CCA AGG TGG CTG GTA AC
Nanog F ATA CCT CAG CCT CCA GCA GA
R ATT GTT CCA GGT CTG GTT GC
NCAM-1 F TTG TTT TTC CTG GGA ACT GC
R ATC CTC GCC TGT AAC CAC AC
Neogenin F AGA GGG CAT GAG TCA GAG GA
R GCT GGA GTG GAA ATG ATG GT
NRP1 F CCA CAG TGG AAC AGG TGA TG
R GCA CGT GAT TGT CAT GTT CC
Nestin F AGA GAA CCA GGA GCC ACT GA
R TTC TCT TGT CCC GCA GAC TT
Oct4 F CTT GCT GCA GAA GTG GGT GGA GGA A
R CTG CAG TGT GGG TTT CGG GCA
Olig2 F AAG TCA TCC TCG TCC AGC AC
R GCG GCT GTT GAT CTT GAG AC
Otx2 F ACA AGT GGC CAA TTC ACT CC
R ATG CCC CCA AAG TAG GAA GT
Pax6 F GGC AAC CTA CGC AAG ATG GC
R TGA GGG CTG TGT CTG TTC GG
Sema3A F TGG ACA TCA TCC TGA GGA CA
R CAA AGT CTC GCC CCA TAA AA
Table 2. Continued
Gene Nucleotide Sequence
Sema3C F CTG TTG TGA CGG ACA AA TGG
R ATC TCC CTG CTG ATG TTG CT
Sema6A F GCA CAA CCA CAT CAG ATT CG
R GCT GTC AGG TGA GTC AAG CA
Slitrk1 F AAC GTT ACA GGG GAC GTT TG
R GAA ACG CTG CAG ACT TGT GA
Slitrk2 F TGC AGT CAT TCA GGA AGG TG
R GCT CTG CAG TCC ATC AAA CA
Slitrk3 F TGT TCC GAG GCC TAC AGA GT
R GTC TGT TGG CAG AGT CCT CA
Slitrk4 F TCA GCC CTG ATT TCT TCG ACA
R CTC ACA GTT GAC ATA GAG CAC AT
Slitrk5 F GTG ACA TTG TGG GCA TGA AG
R GTG TGG GCG TGG AAA CTA CT
Slitrk6 F TAT GGT CAC CAC TCC TGC AA
R AAC CAC TAT CCC TGC AGC AC
Sox1 F CAA TGC GGG GAG GAG AAG TC
R CTC TGG ACC AAA CTG TGG CG
UBE2NL F CCT TTG AGG GAG GGA CTT TT
R GCC TGG ATC GAT AGC AGA AC
VAChT F TAC CCT ACG GAG AGC GAA GA
R GGC GAA CAG GAC TGT AGA GG
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